Advancing Truth in Oncology by Complementing Clinical Trials With Evidence From Clinical Practice
Menée au Japon à partir de données portant sur 1 245 patients âgés atteints d'un cancer du poumon non à petites cellules de stade avancé (âge médian : 78 ans), cette étude de cohorte rétrospective évalue l'efficacité, du point de vue de la survie sans progression et de la survie globale, et la toxicité de l'ajout d'une chimiothérapie à une immunothérapie de première ligne
Despite the increasing complexity of cancer clinical trials, the most successful trials often answer simple questions of efficacy for populations of patients with the most generalizable characteristics and adequate organ function. Unfortunately, as a result, specific populations of patients, such as older adults, who may be frail or have other comorbid conditions, can often be overlooked. In this issue of JAMA Oncology, the case series by Tsukita et al presented the results of an analysis from an impressive network of Japanese oncology sites, collating data that answer an important clinical question of relevance to patients with non–small cell lung cancer who are older than 75 years of age. These types of efforts are needed by both patients and clinicians and are often sorely lacking in oncology.
JAMA Oncology 2024